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ABSTRACT 
Many genetic variants have been identified to associate with circulating levels 
of hemostatic proteins and with thrombotic or hemorrhagic disorders. 
However, the underlying molecular mechanisms remain largely unknown.  
The overall aim of this thesis was to study how genetic variation and epigenetic 
mechanisms influence the regulation of hemostatic gene expression. The 
specific aims were to investigate epigenetic mechanisms regulating tissue-type 
plasminogen activator (t-PA) gene expression in the human brain (Paper I); to 
identify cis-acting variants involved in hemostatic gene regulation in liver 
(Papers II and III); and to investigate whether DNA methylation patterns in 
hemostatic genes in blood can reliably predict those in liver (Paper IV). 
In Paper I, human astrocytes and neurons were treated with histone deacetylase 
(HDAC) inhibitors. Protein and mRNA levels of t-PA were measured using 
ELISA and real-time qPCR, respectively. Histone modifications were assayed 
with chromatin immunoprecipitation, and DNA methylation analysis of the t-
PA promoter was performed by bisulfite sequencing.  
In Papers II-IV, liver tissue and blood samples were collected from patients 
undergoing liver surgery and targeted DNA-, RNA- and methylation 
sequencing was performed for 35 hemostatic genes with predominant 
expression in the liver. These data were used in Papers II and III to performed 
allele-specific analyses of mRNA expression (ASE) and DNA methylation 
(ASM) in liver. In Paper IV, the extent to which blood can be used as a 
surrogate for DNA methylation of hemostatic genes in the liver was 
investigated. 
In Paper I, cell treatments with HDAC inhibitors resulted in an increase in t-
PA mRNA and protein expression, and in a significant increase in histone H3 
acetylation. DNA methylation analysis revealed that the t-PA promoter was 
hypomethylated in neurons, astrocytes, and in post-mortem brain tissue, which 
indicates active transcription. In Paper II, ASE was identified in 60% of the 
hemostatic genes studied and 14 novel genotype-expression associations were 
discovered. In Paper III, a detailed DNA methylation map of the targeted 
hemostatic genes in liver was created, and novel associations between SNPs 
and DNA methylation were identified. The analyses performed in Paper IV 
showed that the correlation of hemostatic gene methylation between liver and 
blood was generally low. However, about 3% of the investigated CpGs had 
methylation levels that were significantly correlated between the two tissues, 
 and for these, blood may potentially be used as a surrogate tissue to detect liver 
methylation.  
Taken together, these findings highlight the importance of integrating genetic, 
epigenetic, and expression analyses in the relevant tissue, and demonstrate that 
this approach can contribute to new insights into the biological processes 
affecting hemostasis and thrombosis. 
Keywords: 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Hjärtinfarkt och hjärninfarkt (även kallad ischemisk stroke) är bland de 
vanligaste dödsorsakerna i Sverige i dag, och hjärninfarkt är den enskilt största 
orsaken till bestående funktionsnedsättning hos vuxna. En infarkt uppstår 
oftast till följd av en blodpropp i ett tillförande kärl vilket leder till syrebrist 
med efterföljande vävnadsskador. Blodproppar kan även uppstå i de kärl som 
återför blodet i form av djup ventrombos eller lungemboli. En blodpropp kan 
bland annat uppstå till följd av rubbningar i blodets levringsprocess, även 
benämnd hemostas. Hemostasen är en essentiell process i kroppen vars uppgift 
är att stoppa blödningar och samtidigt undvika blodproppar. Systemet är 
komplext och involverar många olika typer av proteiner. Två centrala delar i 
hemostasen är koagulering, vilket innebär att blodet levrar sig för att täppa till 
och slutligen reparera en kärlskada, och fibrinolys, som är kroppens eget 
system för att lösa upp blodproppar. Det är av yttersta vikt att balansen i alla 
system som är involverade i hemostasen är noggrant reglerad. Blir balansen 
förskjuten i ena riktningen ökar risken för blodproppar och infarktsjukdomar, 
och blir balansen förskjuten i motsatt riktning ökar risken för blödningar. 
 
Genom åren har flera genvarianter kunnat kopplas till förändrade nivåer av 
koagulationsproteiner och fibrinolysfaktorer, och även till en ökad risk för 
blodpropp, infarktsjukdomar eller blödningar. Genom vilka molekylära 
mekanismer dessa genvarianter har sin effekt är dock till stor del fortfarande 
okänt. I de delarbeten som presenteras i den här avhandlingen har vi därför valt 
att studera hur vissa genetiska och molekylärgenetiska (epigenetiska) 
mekanismer kan påverka uttrycket av flera gener som styr hemostasen. 
 
Vi har främst studerat två olika typer av epigenetiska mekanismer: DNA-
metylering och histonmodifieringar. DNA-metylering är en kemisk 
modifiering av det genetiska materialet, DNA, som innebär att en metylgrupp 
adderas till en eller flera positioner i DNA-molekylen. Histonmodifieringar 
innebär olika typer av förändringar på de proteiner, histoner, som organiserar 
DNA-molekylerna i cellkärnan. Båda dessa mekanismer har tidigare visats 
kunna påverka geners uttrycksnivåer. I delarbete I fann vi att 
histonmodifieringar i genen som kodar för den viktiga fibrinolysfaktorn 
vävnadsplasminogenaktivator, förkortat t-PA, var förknippade med uttrycket 
av denna gen i hjärnan, och att denna process sannolikt även involverar DNA-
metylering. Genen som kodar för t-PA är normalt högt uttryckt i hjärnan där t-
PA-proteinet, utöver hemostasen, även är involverat i flera andra processer 
såsom inlärning och vid återhämtning av funktioner efter hjärninfarkt. 
 
 Vid epigenetiska studier, såväl som vid studier av genuttryck, är det av stor 
vikt att undersöka just den vävnad som genen eller generna av intresse är 
uttryckta i. Detta på grund av att både epigenetiska mekanismer och genuttryck 
kan variera stort mellan olika vävnader i kroppen. Många av de proteiner som 
styr hemostasen uttrycks och produceras till största del i levern, varifrån de 
sedan utsöndras till blodets cirkulationssystem. I delarbetena II-IV studerade 
vi därför 35 hemostasgener som framförallt uttrycks i levern. I delarbete II 
studerade vi hur genvarianter påverkar uttrycket av dessa gener, och 
identifierade ett flertal tidigare okända kopplingar mellan genetiska varianter 
och uttrycket av hemostasgener. I delarbete III presenterade vi för första 
gången en detaljerad bild över metyleringsmönstret i dessa 35 hemostasgener 
i levervävnad. Vi identifierade nya kopplingar mellan genetiska varianter och 
graden av DNA-metylering i dessa gener i levern. I delarbete IV undersökte vi 
i vilken grad DNA-metyleringen i de 35 hemostasgenerna i blod kan spegla 
metyleringsmönstret i levern. Vi fann att för den absoluta majoriteten av 
metyleringspositioner förelåg ingen korrelation mellan metyleringsgraden i 
blod och lever inom samma individ. Resultaten visar således att blod bara kan 
användas för att undersöka metyleringsmönster i lever för ett fåtal bestämda 
positioner i genomet. 
 
Sammantaget visar resultaten från den här avhandlingen att både genetiska och 
epigenetiska mekanismer har betydelse för regleringen av uttrycket av ett 
relativt stort antal gener som styr hemostasen. Genom modern 
sekvenseringsteknik som genererar stora datamängder och avancerade 
analyser har vi lyckats skapa en detaljerad karta över dessa samband, och 
identifierat nya kopplingar mellan genetik, epigenetik och genuttryck. 
Slutligen visar resultaten att det för epigenetiska studier är av stor vikt att 
undersöka dessa mekanismer i den mest relevanta vävnaden.
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INTRODUCTION 
Basic genetics 
Within most of the different cell types in the human body lies a cell nucleus. 
The nucleus is the core organelle in which the DNA (deoxyribonucleic acid) 
resides. Human DNA is arranged in two copies of 23 large molecules called 
chromosomes. One member of each chromosome pair is inherited from the 
mother, and the other one from the father. Chromosomes 1–22 are autosomal, 
and all genes and elements located on these thus occur in two versions in each 
cell - the maternal allele and the paternal allele. The last pair are the sex 
chromosomes, which contains two X chromosomes for females and one X 
chromosome and one Y chromosome for males.1 
A human DNA molecule is organized as two complementary spiral-shaped 
strands. Each strand consists of a sugar-phosphate backbone and the four 
nucleotide bases: cytosine (C), thymine (T), adenine (A) and guanine (G). The 
two strands are connected by hydrogen bonds, where C always pairs with G 
and T always pairs with A, into a structure known as a double helix.2 The order 
and combination of these four nucleotides comprises the genetic code, 
containing information for all cellular processes. 
The double helices are folded in several layers by various DNA binding 
proteins, histones being the most abundant type, and organized into 
nucleoprotein complexes, i.e. the chromatin. Cellular processes are mainly 
carried out by ribonucleic acid (RNA) molecules, proteins, and peptides. The 
genes in the DNA contain instructions for how these elements are constructed, 
and this is regulated by reorganization of chromatin packaging. Actively 
transcribed genes tend to be located in loosely packed chromatin regions 
known as euchromatin, whereas inactive genes are located in the more densely 
packed heterochromatin. The reorganization of chromatin and the resulting 
gene regulation is an ongoing, dynamic process that varies between cell-types, 
time points, and in response to both internal and external factors.3,4 
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The central dogma 
Three main mechanisms are involved in the processing and interpretation of 
the genetic code: 1) replication, 2) transcription, and 3) translation. Replication 
occurs when two identical copies of a DNA molecule are produced, using the 
original molecule as a template. This takes place when cells undergo mitosis, 
i.e. divide so that two daughter cells are formed from a single parent cell. 
Transcription is the process in which the information in genes is copied and 
stored in molecular templates which will be used to produce proteins. These 
templates are single-stranded nucleic acids called messenger RNA (mRNA). 
The mRNA consists of three of the same bases as DNA: C, A and G, but with 
uracil (U) being the fourth base instead of T. The mRNA molecule is a 
complimentary copy of the DNA sequence comprising the gene in question. 
The last step, translation, is the process in which the mRNA templates are read 
and the stored information is interpreted. The mRNA is decoded in the 
translational machinery, the ribosome, which links amino acids together in the 
order specified by the genetic code. The mRNA is read three nucleotides at a 
time. Each group of trinucleotides, or “codons”, specify which amino acid will 
be added next during protein synthesis.1 The principles of the central dogma 
are illustrated in Figure 1. 
 
Figure 1. Principles of the central dogma. DNA is copied during cell division (replication). RNA 
is transcribed into a complimentary copy of the DNA template (transcription). Amino acids are 
assembled into a protein based on the genetic code stored in the RNA (translation).  
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Genetic variation 
The genetic material in the nucleus of each human cell consists of around three 
billion nucleotide base pairs.5,6 Although the genetic differences between 
individuals are very small, they are in no regard negligible. The underlying 
source of genetic diversity is acquired and inherited alterations in the genome. 
There are several types of both small sequence variations, such as single 
nucleotide polymorphisms (SNPs; Figure 2), and larger structural variations, 
such as chromosomal rearrangements or copy number variation (CNV).7 All 
differences between individuals are a consequence of these types of diversity 
in combination with environmental factors.  
 
 
Figure 2. The genomic sequence may differ between individuals due to a substitution of a single 
nucleotide base, a so called single nucleotide polymorphism (SNP), at a specific location in the 
genome. 
  
 4 
A SNP is a substitution of a single nucleotide at a specific locus in the genome. 
If a carrier has the same nucleotide on both alleles, it is classified as 
homozygous for that position, and if it has two different nucleotides, it is 
heterozygous. Depending on where the SNP is located, it can have different 
consequences. SNPs in coding regions are either so called synonymous or non-
synonymous. Synonymous SNPs do not affect the protein sequence and 
represent the vast majority of the coding SNPs. Non-synonymous SNPs either 
cause a change in the amino acid sequence (missense), potentially resulting in 
defective protein isoforms, or introduce a premature stop codon (nonsense) 
which results in a truncated protein. SNPs that fall outside of coding regions 
can also have functional effects, for example by affecting transcription factor 
binding affinity or by affecting splicing or mRNA stability.8 
The alleles of SNPs located in proximity to each other in the genome are 
unlikely to be separated during recombination, and are thus highly correlated. 
Clusters of linked SNPs are referred to as haplotype groups (haplogroups), and 
are useful in the sense that a few SNPs can be used in order to determine the 
alleles of the remaining SNPs within the same haplogroup, within one 
individual. Thus, haplogroup information is essential in the search for genetic 
associations to diseases and other traits, as it reduces the number of SNPs 
required for genome-wide examinations.9 
 
 
Epigenetics 
Epigenetics is the study of variations that do not involve changes in the DNA 
sequence. These mechanisms are essential during developmental processes, 
cell differentiation, X chromosome inactivation and imprinting, and cell- and 
tissue-specific gene expression.10,11 The epigenetic state of an individual’s 
genome varies between tissues. It also changes during developmental 
processes and aging, and can be influenced by environmental factors such as 
diet, life style factors, and various diseases.12 Epigenetics is thus an important 
field in modern medicine as it may help to combine and explain the relationship 
between an individual’s genetic background, environmental factors, and 
disease. Two major epigenetic mechanisms include DNA methylation and 
histone modifications, and both impact chromatin remodeling and gene 
regulation by diverse processes. An illustration of these main epigenetic 
mechanisms is shown in Figure 3. 
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Figure 3. Schematic view of epigenetic mechanisms. DNA methylation involves the addition of 
a methyl group to a cytosine nucleotide. Post-translational modifications occur on histone tails 
which alter their interaction with other nuclear proteins and with DNA. Epigenetic mechanisms 
are responsible for the organisation of chromatin in the cell nucleus.  
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DNA methylation 
DNA methylation is the most stable epigenetic mark, and has been implicated 
in several complex human traits and diseases. Methylation of DNA is the result 
of amination of cytosines, which involves the addition of a methyl group to the 
fifth carbon of the pyrimidine ring, converting the cytosine into a 5-methyl-
cytosine (5mC). Methylation can be maintained during cell division and 
inherited by the daughter cells. This is managed by DNA methyltransferase I 
(DNMT1) which, following replication, recognizes hemi-methylated DNA 
sequences and methylates the cytosines on the newly synthesized 
unmethylated daughter strand using the old methylated strand as a template.11 
Methylation usually occurs on cytosines in a CG sequence context, also known 
as CpG dinucleotides. Over time, methylated cytosines in the CpG context are 
prone to undergo spontaneous deamination. Deamination of methylated 
cytosines will result in conversion of the 5mC to a T base, resulting in a T-G 
base pair mismatch. DNA repair mechanisms will attempt to ameliorate this 
by either changing the T back to a C, thereby restoring the original C-G base 
pairing, or by changing the G base to an A, resulting in T-A base pairing. The 
latter case results in a sequence variant in the DNA. As discussed above, 
sequence variants can have deleterious effects on cell function, and for this 
reason, CpG dinucleotides are depleted in most parts of the genome, compared 
to other nucleotide sequence combinations.13 However, certain genomic 
regions with a high density of CpGs, known as CpG islands (CGI), are also 
present.14 These regions are often located in DNA regulatory elements, such as 
transcription factor binding sites in promoters and enhancers, and CGI 
methylation in these contexts has been shown to repress gene transcription.15 
More recently, however, DNA methylation within gene bodies (i.e. exons and 
introns) has been reported to also be prevalent and to enhance gene 
expression.16-18 Thus, the relationship between DNA methylation and gene 
expression is highly complex and not fully understood. 
In addition to this, DNA methylation can also be influenced by genetic 
variants. In diploid genomes, the two alleles can exhibit different methylation 
patterns, known as allele-specific DNA methylation (ASM). ASM is well 
established in imprinted genes and X chromosome inactivation19, but has 
recently also been identified in autosomes. This type of allelic asymmetry is 
thought to be mostly accounted for by cis-acting regulatory SNPs.20,21 
Therefore, characterizing the relationship between genetic variation and DNA 
methylation could provide insights into mechanisms regulating phenotypic 
diversity, such as susceptibility to certain diseases, and response to drugs and 
environmental agents. 
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Histone modifications 
Histone modifications are, in contrast to DNA methylation, readily reversible 
and are usually not maintained during cell division.22 Histones are the DNA 
binding proteins mainly responsible for the packaging of DNA into 
chromosomes. There are four core types of histones: H2A, H2B, H3, and H4. 
They occur as homodimers under normal circumstances. The DNA is wrapped 
around a histone octamer formed by one dimer of each of the four types, into 
the so-called nucleosomes structure, and these are separated by approximately 
50 bp of DNA. This most basic formation is known as the 10 nm fiber or 
“beads-on-a-string formation”, referring to the resemblance of the 
nucleosomes as beads arranged along a string. This formation is then arranged 
in several higher-order structures, eventually forming the chromatin (Figure 
3).1 
The N-terminal of histones consists of the histone “tail”. Amino acid residues 
in histone tails are exposed to various post-translational modifications such as 
acetylation, methylation, and phosphorylation, among others, which alter their 
interaction with other nuclear proteins and with DNA. The impact of histones 
on gene transcription is governed by chromatin remodeling, and mediated by 
a combination of different types of these modifications. These patterns are 
usually complex, but as a general rule of interpretation, methylation of histones 
is considered to induce gene silencing, while acetylation is considered to 
induce gene activation.23,24  
Histone acetylation is generated and maintained by enzymes known as histone 
acetyltransferases (HAT), and are removed by histone deacetylases (HDAC). 
There is an interplay between histone modifications and DNA methylation, 
and they often act together to recruit various chromatin remodeling complexes. 
For example, methylated DNA can bind various methyl binding proteins 
which, in turn, are able to recruit both HDACs and histone methyltransferases 
(HMTs). HDACs and HMTs can deacetylate and methylate nearby histones, 
and thereby further promote gene repression. Methylated histones also have 
the ability, via binding of various chromodomain proteins, to recruit additional 
DNMTs, which further contributes to DNA methylation and gene 
silencing.22,25 
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Overview of methods for studying the DNA sequence 
Historical aspects 
The structure of the DNA double helix was solved by James Watson and 
Francis Crick as early as 19532, largely based on crystallographic data 
produced by Rosalind Franklin26 and Maurice Wilkins27. Although the 
structure had been described in detail, the technology needed to be able to 
“read” the genetic sequence of DNA from living organisms had not yet been 
developed. The development of sequencing methods was initially focused on 
single-stranded RNA, which is less complex than DNA, and the first methods 
started to appear in the mid-1960s.28-31 The first primitive DNA sequencing 
methods were based on these technologies and were initially performed on 
DNA with “overhanging” 5’ ends from bacteriophages. The overhanging ends 
facilitated the use of DNA polymerase to insert radioactively labeled 
nucleotides which were supplied one at a time while monitoring the sequence 
incorporation. In the early 1970s, this method was adapted with the use of 
oligonucleotides to “prime” DNA polymerase (thereby escaping the need for 
overhanging ends) and could be implemented on all types of DNA.32-34 Around 
this time, advances in electrophoresis (i.e. the separation of particles using an 
electrical charge) were also developed, improving the efficiency and resolution 
greatly.35,36 
Sanger sequencing 
In 1977, Fred Sanger described a novel DNA sequencing approach, the chain-
termination technique, developed at his laboratory.37 This was a major 
breakthrough in sequencing technology, and it largely resembles the methods 
used today. This approach is based on the use of the analog nucleotides 
deoxynucleotides (dNTP) and radioactively labeled, dideoxynucleotides 
(ddNTPs). ddNTP lacks the hydroxyl group required for DNA extension by 
DNA polymerase. When the polymerase synthesizes the complementary 
strand, ddNTPs are occasionally incorporated instead of dNTPs which results 
in termination of the reaction, yielding DNA fragments of various lengths. 
Four reactions, each containing one of the four ddNTP bases (ddATP, ddTTP, 
ddCTP or ddGTP), are performed in parallel and run on a polyacrylamide gel 
by electrophoresis. Autoradiography can then be used to determine the 
nucleotide sequence as the fragments are separated by size. Over the years, 
further improvements have been made to this method and today it is performed 
using fluorescence labeling rather than radioactivity. The four terminating 
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ddNTPs are labelled with fluorophores of different wavelengths, and the DNA 
sequence can then be determined by laser detection of the fluorophores when 
the fragments are separated. This method is still commonly referred to as 
“Sanger sequencing”, after the developer. 
Polymerase chain reaction 
In 1983, biochemist Kari Mullis developed a new method for DNA 
amplification, the polymerase chain reaction (PCR).38 The technique is based 
on thermal cycling and temperature-dependent reactions. In the reaction, the 
double-stranded template DNA is first heated to the point of denaturation. The 
temperature is then lowered to allow binding of oligonucleotide primers to the 
two separated DNA strands, and a DNA polymerase initiates enzymatic 
assembly of two new double strands by incorporating nucleotides available in 
the reaction mixture. This cycle is then repeated, generating an exponential 
amplification of the original DNA template. The PCR method is now widely 
used both for medical diagnostic purposes and in research, and it is one of the 
fundamental steps in modern sequencing techniques. 
Pyrosequencing 
In 1993, yet another sequencing method based on luminescence detection 
using the firefly luciferase enzyme was introduced.39,40 The reaction relies on 
the release of pyrophosphate that occurs when a dNTP is incorporated by the 
polymerase during DNA synthesis, and thus became known as 
pyrosequencing. As with Sanger sequencing, each dNTP is added to the 
reaction one at a time. When the nucleotide is incorporated and pyrophosphate 
is released, the firefly luciferase acts on its substrate luciferin which then 
produces detectible light. The intensity of the light is proportional to the 
number of dNTPs incorporated, thus enabling determination of the number of 
dNTPs incorporated in each PCR cycle. 
Next generation sequencing 
Next generation sequencing (NGS), also denoted massive parallel sequencing, 
first appeared around 2005.41 However, the speed, the number of samples and 
the amount of DNA that can be sequenced per run, and thus the amount of 
output data generated per unit of time has increased exceptionally since the 
development of this new sequencing technology.42 First, 5’ and 3’ adapters are 
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added to each DNA fragment in the sequence library. The DNA fragments are 
then loaded into a flow cell and captured by millions of surface-bound 
oligonucleotides, complementary to the library adapters. Each bound DNA 
fragment is amplified in clonal clusters through bridge amplification. Primers 
attach to the forward or reverse strand and DNA polymerase adds the 
fluorescently labeled nucleotides one by one. Each of the four bases has a 
unique emission which is recorded after each amplification round. NGS also 
allows for multiplexing of several samples in one single run. This is achieved 
by adding sample-specific oligonucleotide indexes, or “barcodes”, to each 
DNA fragment before sequencing. The indexes are sequenced during the 
reaction, and the generated data can be separated based on the sample-specific 
index sequence.43 With these platforms, gigabases of sequence reads can be 
generated simultaneously in one single instrument run44, and the cost for DNA 
sequencing is constantly declining45. Not surprisingly, this new technology has 
thus had a fundamental impact on genetic research.46 
Sequencing of the human genome 
In 1990, long before NGS had been invented, the Human Genome Project was 
launched with the aim to sequence the entire human genome and to identify all 
human genes. It was initiated by the US government, and performed as a large 
international research collaboration overseen by the Human Genome 
Organisation (HUGO).47 In 1998, the private company Celera announced that 
they intended to launch a similar project purposed to proceed faster than the 
HUGO project and at a lower cost.6 Ten years after the HUGO project was 
initiated, the two leaders of the competing groups announced that a first draft 
sequence covering around 90% of the human genome was complete.6,13 The 
finalized genome sequence, covering approximately 99% of the genome, was 
considered complete first two years later, in 2003.5 The publicly funded HUGO 
project thus took thirteen years, and costed approximately 3 billion US 
dollars.48 The private initiative by Celera took five years and costed around 
100 million US dollars to complete.49 However, the Celera project could draw 
on data that had already been made available by HUGO. 
Shortly after the sequence of the human genome was announced, a number of 
large genome projects were initiated. One of the first was the International 
HapMap project50, which was launched in 2002, with the objective to describe 
common genetic variation and to develop a haplotype map of the human 
genome. The last dataset from HapMap was released in 2010. It is based on 
DNA samples from ~1,200 individuals from a variety of human populations51, 
and still remains an important data source for the research community.  
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Another project with a similar ambition is the Encyclopedia of DNA Elements 
(ENCODE). It was launched by the National Human Genome Research 
Institute (NHGRI) in 2003, and intended as a follow-up to the HUGO project.52 
The main focus is to describe the functional elements in the human genome. 
The ENCODE encyclopedia now accommodates information on gene 
expression, promoter activity, transcription factor binding sites, open 
chromatin and chromatin structure, histone modifications, DNA methylation, 
and much more. 
The 1,000 genomes project was an international collaborative project 
conducted between 2008 and 2015, with the aim of sequencing the genomes 
of at least 1,000 individuals using the newly developed sequencing 
technologies.53 The final dataset consists of sequencing data from around 2,500 
individuals, and is the most detailed catalogue of common and rare human 
genetic variation today.54  
One of the largest whole genome sequencing (WGS) projects is the 100,000 
Genomes Project.55 It was initiated in the United Kingdom in 2012 with the 
ambition to sequence 100,000 human genomes from patients in the National 
Health Service, affected by rare diseases and cancer; a goal they met in 2018.56 
Genome-wide association studies 
The sequencing efforts described above, such as the HapMap project and the 
1,000 Genomes Project, have paved the way for genome-wide association 
studies (GWASs). Knowledge of the haplotype structure and linkage 
disequilibrium (LD) between genetic variants has been utilized to develop 
microarray chips for genotyping. Genotyping using these SNP arrays includes 
hybridization of sample DNA with allele-specific oligonucleotide probes, 
which are immobilized on a microarray chip. This allows direct determination 
of the alleles for each SNP included on the chip, but also for many other SNPs 
in the same haploblocks based on LD information. SNP arrays are used in 
GWASs to assay millions of genetic variants across the whole genome in a 
large number of subjects with different traits, or in subjects with or without the 
disease of interest. If one allele is more common in one of the groups at a 
genome-wide significance level, it is considered to be associated with the 
disease or trait in question. 
Through GWASs, a large number of SNPs throughout the genome have now 
been associated with different quantitative traits such as height57, blood 
pressure58, and susceptibility to complex diseases such as coronary heart 
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disease59, stroke60, diabetes mellitus61, and Alzheimer’s disease62. 
Furthermore, SNPs may not only affect disease susceptibility, but also the 
severity and outcomes of diseases63, as well as the response to treatments and 
drugs64. Genetic variants, such as SNPs, are thus of great interest in the current 
era of personalized drug development and precision medicine. 
Quantitative trail loci and allele-specific approaches 
Studies of the effects of SNPs on more intermediate traits are often performed 
by quantitative trait loci (QTL) studies. They are commonly conducted in a 
large sample with genotypic and phenotypic data.  
Expression quantitative trait loci (eQTL) studies links variations in genotypes 
to mRNA expression across individuals and is one approach to elucidate 
whether genetic variants correlate to gene expression.65 Several databases have 
been developed to collect eQTLs for different human tissues and cells, 
including the Genotype-Tissue Expression (GTEx) portal66. Similar to eQTL, 
methylation QTL (mQTL) studies, which link variations in genotypes to DNA 
methylation, can be used to study correlations between genetic variants and the 
methylation level or pattern of specific CpGs, genes, or regions.67  
An alternative approach to the eQTL and mQTL studies is to perform analyses 
of allele-specific expression (ASE) and methylation (ASM). ASE is a 
quantitative phenomenon that results in a bias in the ratio of transcripts from 
the two alleles.68 and has been successfully used to identify a few functionally 
important regulatory variants in hemostatic genes69-71. ASE occurs when 
transcription from one allele is selectively silenced or enhanced, or when 
transcripts undergo selective post-transcriptional degradation (e.g., nonsense-
mediated decay). By comparing expression of alleles within the same 
individual, each allele acts as an internal control for confounding factors (e.g., 
trans-acting effects and environmental confounders) that may alter the overall 
expression of that gene.72 ASM has been demonstrated to be widespread 
among autosomal non-imprinted genes.73 This analysis relies on the presence 
of heterozygous SNPs on the same read as a given CpG site to separate alleles 
prior to analysis. DNA methylation levels at individual CpG sites between the 
two alleles are then directly compared between the two alleles. 
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Hemostasis 
Hemostasis is the physiological process that regulates the intrinsic balance in 
order to maintain intravascular blood circulation and prevents blood loss after 
a vessel injury. The system is complex and involves three major processes. 
Primary hemostasis is the formation of a platelet plug, and it is initiated by 
adhesion of platelets to collagen fibers at the site of vessel injury. Secondary 
hemostasis involves blood clot formation and generation of the coagulation 
factor thrombin. Fibrinolysis is the endogenous breakdown of fibrin, which 
dissolves the clot when the injury is repaired. These processes are heavily 
regulated both by positive and negative feedback systems to prevent 
thrombotic events as well as excessive bleeding. 
Primary hemostasis 
Primary hemostasis involves three sequential steps: platelet adhesion, platelet 
activation, and platelet aggregation. Platelets, or thrombocytes, are circulating 
anucleate cells originating from the bone marrow. In the event of an injury to 
the blood vessel, platelets adhere to the damaged area through a series of events 
involving interaction of the platelet membrane receptor glycoprotein (GP) Ib-
V-IX complex with the immobilized form of von Willebrand factor (vWF) on 
exposed extracellular matrix (ECM), and of the receptor GPVI on the platelet 
to exposed collagen at the site of injury. Platelet activation is initiated 
immediately following adhesion, in response to further interactions between 
cell surface receptors with factors in the exposed collagen. GPVI signaling also 
increases platelet secretion of thromboxane A2 (TXA2), which acts on the 
platelet's own cell surface receptors, and those of other platelets. These and 
other receptors trigger intracellular signaling pathways that convert different 
G protein coupled receptors to their active form, eventually initiating platelet 
aggregation, granule secretion of various coagulation factors and chemotactic 
agents, integrin activation, and cytoskeleton remodeling.74,75 
Secondary hemostasis 
Secondary hemostasis consists of the coagulation cascade and involves an 
array of reactions catalyzed by serine proteases, eventually resulting in the 
cleavage of fibrinogen by thrombin, to generate fibrin. Vessel injury can 
initiate this cascade through the release of tissue factor (TF) from extravascular 
tissues. TF is then exposed to the circulating serine protease factor VII (FVII), 
which it activates. The two form a complex which activates FIX and FX. FX 
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is further activated by the active form of FIX (FIXa) and its cofactor FVIIIa. 
Finally, FXa activates prothrombin to generate thrombin, with the help of its 
cofactor FV. Thrombin is responsible for the cleavage of fibrinogen to generate 
insoluble fibrin which forms a crosslinked mesh at the site of an injury, in 
which red blood cells and platelets are trapped. Thrombin also activates 
platelets via cleavage of the protease-activated receptor (PAR) 1 and PAR4, 
which are responsible for the positive feedback mechanisms critical for clot 
generation.76-78  
In contrast to this, thrombin is also a key player in the downregulation of 
coagulation. Here, thrombin binds to thrombomodulin on the surface of 
endothelial cells, thereby activating protein C which, in turn, cleaves and 
inactivates FVIIIa and FVa, together with the cofactor protein S.79,80 The 
coagulation cascade is further down-regulated by various serine protease 
inhibitors including antithrombin (inhibiting thrombin, FXa, FIXa and FXIa); 
heparin cofactor II (which also inhibits thrombin); protein Z-dependent 
protease inhibitor (an inhibitor of FXa); protein C inhibitor (the inhibitor of 
activated protein C); C1-inhibitor (which inhibits FXIa); and tissue factor 
pathway inhibitor (inhibiting FXa); and alpha-2-macroglobulin (which inhibits 
thrombin).81 
Fibrinolysis 
Dissolvement of blood clots is necessary to avoid thrombus formation in 
healthy vessels. Fibrinolysis is initiated when the serine protease tissue-type 
plasminogen activator (t-PA) binds to the surface of a fibrin clot. t-PA 
facilitates dissolution of fibrin-containing blood clots through cleavage of 
plasminogen into active plasmin which degrades fibrin.82 Fibrin potentiates the 
ability of t-PA to activate plasmin and thus systematic fibrinolysis does not 
generally occur in the absence of fibrin clots.83 The fibrinolytic activity is also 
regulated by plasminogen activator inhibitor type 1 (PAI-1), which inhibits t-
PA, and alpha-2-antiplasmin, which inhibits thrombin.81 In addition, thrombin-
activatable fibrinolysis inhibitor (TAFI) reduces plasmin activity by 
modification of the fibrin residues necessary for the binding of plasmin to 
fibrin.84 
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Liver and hemostatic gene regulation 
While the hemostatic system mainly acts within the vascular compartment, a 
relatively large proportion of the hemostatic proteins originate from the liver85, 
and it is well known that patients with liver disease often display coagulation 
abnormalities86. Given this background, we have in Papers II-IV chosen to 
focus on the regulation of hemostatic genes specifically in liver tissue. 
Genetic variation and circulating hemostatic proteins 
Several mutations and SNPs have been identified that affect circulating levels 
or activity of hemostatic proteins. Hemophilia A and B are X-linked hereditary 
bleeding disorders caused by mutations in the genes encoding FVIII and FIX, 
respectively.87 Similarly, autosomal mutations in the genes encoding FXI88 and 
vWF89 have been shown to cause bleeding disorders due to decreased levels of 
the respective proteins. There are also mutations in the genes encoding 
antithrombin90, protein C91, and protein S92 that give rise to thrombotic 
disorders, and mutations in the genes encoding the fibrinogen subunits93, 
prothrombin94,95 and FV96,97 have been associated with both bleeding and 
thrombotic events. 
With regards to common variants, initial studies employed the candidate gene 
approach. Examples of SNPs within hemostatic genes that have been robustly 
associated with the respective plasma protein level using this approach include 
the common 4G/5G polymorphism in the promoter of the gene encoding PAI-
1 (SERPINE1). The PAI-1 4G allele has consistently been associated with 
higher PAI-1 activity.71,98 Two variants in the β-fibrinogen promoter (-455G/A 
and -854G/A) have been consistently associated with fibrinogen levels99-102, 
and two variants in the FVII gene (-40IG/T and -402G/A) have been linked to 
plasma FVII levels103. Later, several genome-wide association studies on 
circulating hemostatic factors have been performed and identified loci 
associated with plasma concentrations or activity of circulating hemostatic 
proteins such as fibrinogen104,105, FVII106,107, FXI108, TAFI109, and factor VII-
activating protease (FSAP)110. 
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Epigenetics and hemostasis 
A growing body of evidence has indicated an important role for epigenetic 
mechanisms in the regulation of platelets and plasma proteins involved in 
blood coagulation.111 Over the last few years, technological advances have 
made it possible to perform so called epigenome-wide association studies 
(EWASs). An EWAS is performed similarly to a GWAS, but focusing on 
epigenetic variation (commonly DNA methylation) instead of genetic 
variation.112 With regards to thrombotic diseases, EWASs have identified 
several CpGs that are differentially methylated in cases with myocardial 
infarction (MI) or ischemic stroke compared to controls.113-116 A recent large 
EWAS also identified differential methylation in relation to cardiovascular risk 
factors, and a methylation-based risk score was significantly associated with 
incident cardiovascular events in the Framingham offspring study.117 Another 
recent EWAS performed on population-based cohorts from the USA and 
Europe also found that the methylation level of several CpG sites was 
associated with incident MI and coronary heart disease (CHD), and Mendelian 
randomization analyses further supported a causal effect of DNA methylation 
on incident CHD.118 However, in contrast to GWASs on traits such as coronary 
artery disease (CAD) and stroke that have identified association for variants in 
several hemostatic genes60,119, EWASs have so far not implicated a role for 
hemostatic gene DNA methylation in thrombotic disorders. 
Role of hemostatic proteins in arterial and venous thrombosis 
An increased concentration or activity of circulating prothrombotic proteins, 
or a decreased concentration or activity of antithrombotic/fibrinolytic proteins, 
can lead to a prothrombotic state and an increased risk of arterial or venous 
thrombosis.120 Consequently, there have been a large number of studies 
performed on circulating hemostatic proteins and myocardial infarction, 
ischemic stroke, and venous thromboembolism (VTE). Associations between 
increased concentrations of some prothrombotic proteins such as 
fibrinogen121,122, FVII123-125 and PAI-1126-130 and incident both myocardial 
infarction and ischemic stroke have been convincingly demonstrated. Our 
group and others have also found increased plasma concentrations of several 
prothrombotic factors in patients that have suffered from ischemic stroke 
compared to controls.131-137 Similar findings have been made for case control 
studies on CAD.138,139 
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Role of hemostatic proteins in the central nervous system 
Apart from the important functions in the vascular compartment, some 
hemostatic proteins also influence various processes in the brain. The brain has 
a unique system for hemostatic regulation, where the antithrombotic and 
fibrinolytic pathways appear to be less active compared to other tissues, in 
order to protect against hemorrhage.140 For example, concentrations of the 
anticoagulants tissue factor pathway inhibitor (TFPI) and thrombomodulin are 
very low in the brain141,142, whereas the principal initiator of coagulation, tissue 
factor, is expressed at high levels by astrocytes143,144.  
Among the hemostatic proteins most extensively studied in the central nervous 
system (CNS) is t-PA. In the CNS, t-PA is not only synthesized in endothelial 
cells but also in neurons and glial cells such as astrocytes.145,146 It has been 
implicated in several different important physiological processes including 
synaptic plasticity and memory/learning. t-PA gene expression increases 
during the late phase of long-term potentiation (L-LTP), a cellular system for 
memory formation, and in certain neurons in the cerebellum during activity-
dependent plasticity.147,148 The exact molecular mechanisms by which t-PA 
facilitates these processes are not yet fully elucidated, but several plausible 
explanations have been put forward. For example, t-PA is known to associate 
with certain cell surface receptors including the N-methyl-D-aspartic acid 
receptor (NMDAR) and the low-density lipoprotein receptor-related protein 
(LRP). This leads to an enhanced efficiency of intracellular signaling149 and 
subsequently in structural remodeling of synapses, synaptic plasticity and 
activity-dependent learning150-152. t-PA is also believed to be involved in 
processes regulating brain plasticity through its ability to cleave and activate 
plasminogen into plasmin. Active plasmin can, in addition to fibrin 
degradation, convert the precursor of brain derived neurotrophic factor 
(BDNF) into mature BDNF, a key protein in the regulation of L-LTP.153 
Evidence that t-PA is involved in neurotoxic processes has also been proposed. 
Following cerebral ischemia or traumatic brain injury, large amounts of t-PA 
are released into the extracellular space by activated glial cells and neurons. 
This results in cleavage of NMDA receptors and subsequently in an over-
excitation of neurons, and neuronal cell death.154 High concentrations of t-PA 
may also induce opening of the blood brain barrier (BBB), through a process 
involving the interaction of t-PA with LRP.155 Other potential mechanisms 
have also been put forward, suggesting that t-PA regulates these processes 
through several different actions.156 In Paper I, we thus chose to investigate t-
PA expression in human neurons and astrocytes. 
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AIM OF THE THESIS 
The overall aim of this thesis was to study the influence of genetic and 
epigenetic variation on the regulation of hemostatic gene expression. 
The specific aims were: 
 
Paper I 
To test the hypothesis that epigenetic mechanisms regulate the expression of 
the gene encoding tissue-type plasminogen activator within the human brain 
Papers II and III 
To map the gene expression and DNA methylation patterns of hemostatic 
genes predominantly expressed in the human liver 
Papers II and III 
To use allele-specific expression and DNA methylation analyses to identify 
putative cis-acting variants involved in hemostatic gene regulation in human 
liver 
Paper IV 
To investigate whether DNA methylation patterns in hemostatic genes in 
blood can reliably predict those in liver  
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SUBJECTS AND METHODS 
Material 
The following biological material has been used for the analyses described in 
this thesis. 
Paper I 
• Primary human astrocytes derived from two different individuals 
• Primary human neurons derived from two different individuals 
• Human post-mortem hippocampal and cortical brain tissue from ten 
individuals 
Papers II-IV 
• Human liver tissue and peripheral blood samples from 27 
adult individuals 
 
Cell culture 
For Paper I in this thesis, we utilized primary cultures of two types of human 
cells derived from the brain. Astrocytes represent a large proportion of all glial 
cells in the brain.157 Their main functions include biochemical support of the 
endothelial cells that form the BBB and to provide neurons with nutrients, but 
they also play a role in tissue repair following brain injuries.158 Neurons are the 
primary cell type in the nervous system where they are specialized in 
processing and transmission of cellular signals in both chemical and electrical 
forms. Neurons and astrocytes are both producers of t-PA in the CNS.145  
In vitro culturing of cells is a laboratory technique that is fundamental in many 
fields of medical research. The cells may be isolated from a living tissue 
directly, or they may be derived from an already established cell line. A key 
advantage of in vitro experiments is that cells can be maintained and grown 
under carefully controlled conditions, thereby eliminating many cofounders 
caused by external factors. However, it should be noted that cultured cells are 
grown in an artificial setting that cannot accurately simulate the internal 
environment in the living tissue. Thus, results from cell culture experiments 
should always be interpreted with caution as they may not be applicable in the 
in vivo context. Furthermore, primary cells have a shorter life span in cultures 
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compared to established cell lines. However, they are still considered to 
maintain more of the normal features and functions seen in cells in vivo.159 
Cell culture and treatments of human neurons and astrocytes 
(Paper I) 
Human primary astrocytes derived from two individuals (ScienCell, San 
Diego, CA, USA) were cultured in astrocyte growth medium (AGM) 
supplemented with 2% fetal bovine serum, 1% astrocyte growth supplement 
and 1% penicillin/streptomycin solution (ScienCell). Astrocytes were split and 
subcultured using trypsin-EDTA (0.25 mg/ml, ScienCell) treatment. Human 
primary neurons (ScienCell) from two individuals were cultured on poly-l-
lysine-coated flasks (ScienCell) in neuronal medium supplemented with 1% 
neuronal growth supplement and 1% penicillin/streptomycin solution 
(ScienCell). Cultured cells were kept at 37°C and 5% CO2 in a humidified 
environment. The medium was replaced in the first two days and every two to 
three days thereafter. 
To evaluate the influence of histone modifications on t-PA gene expression, 
both types of cells were treated with two different inhibitors of HDAC, 
trichostatin A (TSA) and MS-275. HDAC inhibitors are a class of compounds 
that increases acetylation of lysine residues in histones by inhibiting the 
activity of HDAC enzymes. TSA inhibits class I and class II HDACs, whereas 
MS-275 specifically inhibits class I HDACs. TSA (1 µM) and MS-275 (10 
µM) were prepared in dimethyl sulfoxide (DMSO) and diluted in 
supplemented astrocyte growth medium for astrocyte cultures or in 
supplemented neuronal medium for neuron cultures. Control cultures were 
exposed to the maximum final concentration of DMSO (0.1%). Cells were 
treated for 14 or 24 hours, and all stimulations were performed in six separate 
cell culture wells (n = 6) per cell type and treatment time. Astrocyte treatments 
were performed at passage three and on cells of 100% confluence. Neuron 
treatments were preformed once the seeded cells were fully differentiated. Cell 
culture media was collected and stored at -20°C. Cells were lysed with TRK 
buffer (Qiagen, Hilden, Germany) supplemented with 20 µL β-
mercaptoethanol per ml TRK, and extracts were then collected and stored at 
−80°C, until further analysis. Concentrations of TSA and MS-275 were 
selected to be appropriate for cell treatment with regard to their respective half 
maximal inhibitory concentration (IC50) measures. 
For the chromatin immunoprecipitation (ChIP) assay, primary human 
astrocytes were cultured as described above, in 15 cm plates and allowed to 
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reach approximately 80% confluence. Cells where then treated with the same 
concentrations of TSA (1 µM), MS-275 (10 µM), or DMSO vehicle control 
(0.1%) for 24 hours. Following treatments, the culture medium was removed 
and replaced by serum-free astrocyte growth medium supplemented with 1% 
formaldehyde to induce chromatin cross-linking. Plates were incubated with 
formaldehyde for 10 minutes at room temperature and then washed with ice 
cold phosphate-buffered saline (PBS). The fixation process was stopped by the 
addition 1 x glycine/PBS buffer for five minutes and the cells were then 
washed in cold PBS one more time. Fixed cells were harvested using a rubber 
policeman and a cell-scraping solution consisting of cold PBS supplemented 
with 30 µL of 100 mM phenylmethylsulfonyl fluoride (PMSF), and then 
pelleted by centrifugation for 10 minutes at 720 RCF and 4°C. The supernatant 
was discarded, 1 µL 100 mM PMSF + 1 µL protein inhibitor cocktail (PIC; 
Active Motif, Carlsbad, CA, USA) was added, and the pellet was stored in -
80°C until further analysis. Since ChIP requires a relatively large amount of 
cross-linked DNA, this assay could not be performed on neurons, as they do 
not proliferate in cultures. 
 
Human brain tissue 
In addition to the in vitro cell culture experiments in Paper I, we also performed 
DNA methylation analyses on DNA isolated from human hippocampal and 
cortical brain tissue. Cerebral cortex makes up the outer layer of the brain and 
is the main site of neural integration.160 The hippocampus is part of the limbic 
system and consists of two structures, one in each hemisphere of the brain, and 
plays a fundamental role in memory consolidation.160 The benefit of studying 
whole tissue compared to cultured cells is that it offers a more in vivo-like 
environment, where the biological and chemical nature of the tissue is 
preserved. However, as whole tissue consists of several different cell types with 
potentially different DNA methylation signatures, there is always a risk that 
methylation studies on whole tissue may be confounded by cell-type 
composition bias. 
Human brain tissue collection (Paper I) 
Fresh frozen hippocampal and cortical brain tissue samples from 10 unrelated 
individuals were provided by the Neurological Foundation of New Zealand 
Human Brain Bank. There were no evident neurological injuries associated 
with the cause of death, and the assessment of all brains by a neuropathologist 
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revealed no neurological abnormalities. Mean post-mortem delay was 13 hours 
(range 7–21 hours). 
 
Human liver 
The liver plays a major role in producing proteins that are secreted into the 
blood, and as outlined in the Background, many circulating proteins involved 
in hemostasis are primarily produced in the liver. Thus, in Papers II-IV, we 
studied DNA methylation and gene expression of hemostatic genes in liver. 
Human liver tissue and blood sample collection (Papers II-IV) 
Human liver tissue and venous blood samples were collected from adult 
individuals of European descent undergoing liver surgery at the Sahlgrenska 
University Hospital, Gothenburg, Sweden. The reasons for surgery were 
secondary malignant neoplasm of the liver and intrahepatic bile duct or liver 
cell carcinoma. The liver tissue samples collected for this study were as distant 
as possible to the metastasis/carcinoma. Samples had to be non-cirrhotic and 
non-tumorous on macroscopical examination by the surgeon to be included in 
the studies. During the liver resection, non-tumorous tissue (size 
approximately 0.5 cm3) was collected and placed in RNAlater at 4°C for 3 to 
4 days, then aliquoted and stored at –80°C.  
Initially, 20 paired liver and blood samples were collected. Genomic DNA 
(gDNA) isolation and sequencing was successful for 19 blood samples. High 
quality RNA was successfully isolated and sequenced from 18 liver samples, 
and both data types were available for 17 paired samples. gDNA extraction 
from liver tissue and subsequent bisulfite sequencing was successful for all 20 
samples. Paper II is based on data from the 17 paired blood DNA/liver RNA 
samples, and Paper III is based on the 19 paired samples with data from both 
blood DNA (for genotyping) and liver DNA (for methylation analysis). At the 
time of the initiation of the study described in Paper IV, we had collected eight 
additional paired liver and blood samples that were analyzed with regards to 
genotypes and DNA methylation. Thus, Paper IV included data from 27 paired 
samples.  
  
Martina Olsson Lindvall 
23 
mRNA quantification 
Quantitative polymerase chain reaction 
Quantitative PCR (qPCR) is a sensitive method used for mRNA quantification 
and expression analysis. Prior to the qPCR, the target mRNA is converted into 
complementary DNA (cDNA) through a reaction using the DNA polymerase 
reverse transcriptase. This is performed to achieve a more stable nucleic acid 
sequence. There are two common versions of qPCR quantification: TaqMan 
probe-based detection and SYBR green-based detection. In probe-based 
qPCR, the probe consists of a sequence complementary to a region of the target 
genes with a reporter fluorophore covalently bound to the 5’-end and a 
quencher fluorophore bound to the 3’-end. When the fluorophore and quencher 
are located in proximity to each other, the quencher suppresses the fluorophore 
signal. The probe is hydrolyzed with the sample, and is allowed to bind to the 
template strand of the gene of interest. During PCR, the Taq polymerase 
replicates the template to which the probe is bound, cleaves the probe and 
thereby separates the quencher from the reporter. The intensity of fluorescence 
emission increases exponentially as this reaction progresses; this allows for 
determination of the start concentration of target mRNA on the basis of the 
emission intensity. 
The SYBR green assay uses small molecular fluorogenic probes specific to a target 
gene for detection as it accumulates during PCR. The probe fluoresces when it is 
bound to double-stranded DNA. As the DNA is denatured during the PCR, the 
probe is released and fluorophore emission is reduced to a minimum. During 
the extension and polymerization process, the fluorescent probe binds to the 
double-stranded product, resulting in a net increase in the fluorophore signal.  
Taq-man qPCR is considered superior to that of SYBR green as it is useful for 
more applications. Both sensitivity and reproducibility are also considered 
higher compared to SYBR green. Additionally, as SYBR green binds to double 
stranded DNA in an unbiased manner, longer PCR products will emit more 
fluorescence than shorter products. The main disadvantage with TaqMan 
qPCR is that synthesis of different probes is required for each target, which 
can be time consuming and less cost-effective in comparison to SYBR 
green.161 
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RNA sequencing 
mRNA expression can also be calculated from RNA sequencing data. Here, 
expression is quantified by counting the number of sequence reads mapping to 
the gene of interest. Counts are then typically normalized by conversion to 
reads, fragments, or transcripts per kilobase million (RPKM, FPKM, and TPM, 
respectively). For RPKM, the total number of reads in a sample is counted and 
this number is then divided by one million (i.e. resulting in a “reads per 
million” [RPM] factor). The number of reads in a specific gene of interest is 
then divided by RPM, and thereafter by the length of this gene of interest in 
kilobases. The last step is performed to adjust for the fact that a longer gene 
will have more reads than a shorter gene with an identical expression level. 
The FPKM is identical to RPKM with the exception that FPKM was developed 
specifically for paired-end sequence data, and thus takes into account that two 
reads (in a read pair) can correspond to one single fragment. TPM is a newer 
method, but also very similar to RPKM and FPKM. When calculating TPM, 
the number of read counts for each gene is divided by its gene length 
(generating “reads per kilobase”, RPK). After that, the RPK values are 
summed up within each sample and divided by one million, and the RPK value 
for the gene of interest is then divided by this factor. This avoids the potential 
issue with RPKM and FPKM when the sum of normalized reads differs 
between samples, and facilitates direct comparisons between samples of the 
proportion of reads mapping to a specific gene of interest.162 Thus, for our 
analyses of mRNA expression in Papers II and III, we used the TPM method. 
Analysis of t-PA mRNA expression using qPCR (Papers I and II) 
In Paper I, TaqMan Real-Time qPCR (Applied Biosystems, Foster City, CA, 
USA) was used for mRNA expression analysis of t-PA. Total cell RNA was 
isolated from cell extracts using E.Z.N.A. Total RNA Isolation Kit (Omega 
Bio-tek, Norcross, GA, USA), according to the manufacturer’s protocol. The 
concentrations of the isolated RNA samples were measured by NanoDrop and 
determined to be approximately 100 ng/μL per sample. Isolated RNA was 
converted to cDNA using a GeneAmp RNA PCR Kit (Applied Biosystems) in 
a total volume of 20 μL. All samples were normalized relative to the 
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase. The PCR was 
performed in 384-well format on an ABI Prism 7900HT Sequence Detection 
System (Applied Biosystems) in a total volume of 10 μL. Relative 
quantification of mRNA expression was analyzed using the comparative CT 
method and all samples were analyzed in triplicates. Thermocycling conditions 
and probe and primer sequences are thoroughly described in Paper I. 
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Analysis of hemostatic mRNA expression (Papers II and III) 
In Paper II and III, RNA-seq was used to determine mRNA expression of the 
targeted genes of interest. Total RNA was extracted from liver tissue samples 
in biological duplicates (two separate pieces of liver tissue per individual) 
using the AllPrep DNA/RNAmini kit (Qiagen) and sequenced as described 
below. Sequence reads were counted using HTseq (v. 0.6.1) in R, and 
normalized estimates of gene expression in TPM per gene were then 
calculated. 
 
Protein analyses 
There is a variety of different methods for protein quantification. For the 
protein measurements in Paper I, we utilized a commonly used antibody-based 
method called enzyme-linked immunosorbent assay (ELISA). A microtiter 
plate is coated with a known quantity of a capture antibody with specificity for 
the sample antigen. Samples are then added to the wells and are bound by the 
capture antibody. The plate is then washed to remove any unbound antigen 
before a secondary enzyme-linked antibody specific for the antigen is added. 
Finally, a substance with the substrate for the enzyme is added and the reaction 
generates a detectable signal that will be based on the amount of bound 
secondary antibody and thereby the amount of antigen. 
Analysis of t-PA protein concentrations (Paper I) 
Cell culture medium from astrocytes treated with HDAC inhibitors and control 
cultures was collected and t-PA protein concentrations in the medium was 
determined using a sandwich ELISA (TriniLIZE t-PA; Trinity Biotech, Bray, 
Ireland) according to the manufacturer’s protocol. The colour intensities of the 
samples were measured at 490 nm in a Mithras LB 940 (Berthold 
Technologies, Bad Wildbad, Germany).  
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Chromatin immunoprecipitation assay 
Chromatin immunoprecipitation (ChIP) assay is a method used to map the 
DNA target of specific DNA-binding proteins, such as transcription binding 
factors and histones. The technique is based on cross-linkage of the entire 
chromatin in a tissue or living cells by fixation.  The cross-linked chromatin is 
then sheared by enzymes or sonication into smaller fragments, and the regions 
bound to the protein of interest can be extracted using a protein-specific 
antibody. Cross-linkage is then reversed and the DNA is released, purified, and 
analyzed. 
Analysis of histone modifications in the t-PA promoter (Paper I) 
Cell pellets were thawed on ice and resuspended in cold lysis buffer 
supplemented with PMSF and PIC and incubated on ice for 30 minutes. Cells 
were transferred to a cold homogenizer and dounced on ice with a small 
clearance pestle and 10 strokes to aid nuclei release. The samples were then 
centrifuged for 10 minutes at 2,400 RCF at 4°C and the supernatant was 
discarded. The nuclei pellet was resuspended in shearing buffer supplemented 
with PMSF and PIC, and sheared on a Bioruptor Pico (Diagenode, Liège, 
Belgium) sonicator with 25% power at 4°C, with five pulses of 20 seconds 
each, with 30 seconds rest in between. Samples were then centrifuged for 10 
minutes at 18,000 RCF and 4°C, and the supernatant containing the sheared 
chromatin was collected. Ten μL of each sample was removed and stored at -
20°C to serve as the input control. 
The ChIP reaction was performed with rabbit anti-acetyl-histone H3 or anti-
acetyl-histone H4 (1 mg/mL; Merck Millipore, Burlington, MA, USA). A 
negative antibody control (normal rabbit IgG), and a no-antibody control were 
also prepared. All samples were incubated overnight on an end-to-end rotator 
at 4°C, and the captured DNA was eluted by magnetic separation of the beads. 
Both ChIP samples and input DNA samples were incubated at 95°C for 15 
minutes. Following incubation, proteinase K was added to each tube, and 
samples were incubated at 37°C for one hour. Thereafter, the tubes were 
returned to room temperature and proteinase K stop solution was added to each 
sample. Finally, samples were cleaned using the Chromatin IP DNA 
Purification Kit (Active Motif) as recommended by the manufacturer, and the 
captured DNA was quantified using SYBR green detection. Samples were 
analyzed in triplicates on a CFX384 Real-Time PCR Detection System (Bio-
Rad Laboratories, Hercules, CA, USA). A standard curve with 7 points 
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(concentration ranging from 3.2 pg/μl to 50 ng/μl) and a no-templet control for 
the qPCR were included in triplicates. The results were calculated as the 
percentage of input fraction, corrected for background with no-antibody 
controls. The SYBR green qPCR concept is described in detail above. The 
qPCR was performed at TATAA Biocenter in Gothenburg, Sweden. Primer 
sequences and further details can be found in Paper I. 
 
Methylation sequencing of the t-PA promoter (Paper I) 
Total DNA from cultured human astrocytes, neurons, and hippocampal and 
cortical brain tissues was isolated using the E.Z.N.A. Tissue DNA Kit (Omega 
Bio-tek). Isolated DNA was modified with sodium bisulfite using a 
MethylCode Bisulfite Conversion Kit (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s recommendations. Following bisulfite 
conversion, three overlapping regions of the t-PA promoter were amplified by 
a so called “nested PCR”, in which the DNA is amplified in two subsequent 
PCRs. The first PCR is performed with a pair of outer primers flanking the 
target sequence, followed by a second PCR utilizing a pair of inner primers. 
This method has the advantage that it reduces the risk of contamination due to 
unexpected primer binding sites, and provides a higher overall yield than a 
traditional PCR. Conditions for both the primary and the secondary reaction as 
well as primer sequences are reported in detail in Paper I. After each stage of 
the nested PCR the product was purified using the High Pure PCR Product 
Purification kit (Roche, Basel, Swizerland). The PCR product was then 
sequenced directly by Sanger sequencing on an ABI 3130 XL (Applied 
Biosystems), using the forward primers from the nested PCR. Percent 
methylation of all CpGs in the promoter was analyzed using the 4Peaks 
(Nucleobytes, Aalsmeer, The Netherlands) software. 
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Design of a targeted sequencing panel for hemostatic 
genes (Papers II-IV) 
For Papers II-IV, we selected 35 genes with predominant expression in liver 
based on data from the GTEx project66, and related to hemostasis by studies of 
the literature, the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway database163, and the Molecular Signatures Database (MSigDB)164. To 
exploit the full potential of the design, we also included 42 other genes of 
interest for our group. Custom capture kits (Agilent, Santa Clara, California, 
United States) were designed for targeted sequencing of gDNA and for 
methylation analysis using the SureDesign tool (Agilent), and for mRNA using 
eArray (Agilent). For gDNA methylation sequencing, probes were designed to 
capture all exons, introns, and potential upstream and downstream regulatory 
regions, resulting in a 3.3 Mb design. Genomic regions 5,000 bp upstream and 
500 bp downstream of each gene were included in the design. However, for 
the upstream regions we expanded the default 5,000 bp region if we found 
strong evidence for more distal regulatory elements further upstream. For the 
RNA design, exons from all known isoforms of the 35 genes were included, 
plus one negative control and four liver cell-specific markers, resulting in a 0.5 
Mb design. A full list of genes, regions, and transcripts for the 35 genes 
included in the gDNA and methylation sequencing designs, and the negative 
control and liver-specific markers included in the RNA design are shown in 
Table 1. 
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Table 1. Genes and targeted regions included in the custom-designed capture kits for gDNA, 
mRNA and methylation sequencing. Locations are given according to the human reference 
genome hg19. 
Gene name Region included in the capture 
design 
Protein name 
A2M chr12:9,219,804-9,280,558 Alpha2-macroglobulin 
C4BPB chr1:207,257,584-207,273,837 Complement component 4 binding 
protein, beta 
CPB2 chr13:46,626,822-46,684,211 Carboxypeptidase B2 (TAFI) 
F10 chr13:113,774,613-113,804,343 Factor X 
F11 chr4:187,180,618-187,211,335 Factor XI 
F12 chr5:176,828,639-176,844,077 Factor XII 
F13B chr1:197,007,821-197,041,397 Factor XIII B 
F2 chr11:46,732,043-46,761,556 Prothrombin (Factor II) 
F5 chr1:169,480,692-169,560,769 Factor V 
F7 chr13:113,755,105-113,775,495 Factor VII 
F9 chrX:138,607,895-138,646,117 Factor IX 
FGA chr4:155,503,780-155,516,897 Fibrinogen alpha chain 
FGB chr4:155,479,132-155,494,415 Fibrinogen beta chain 
FGG chr4:155,525,228-155,539,402 Fibrinogen gamma chain 
GGCX chr2:85,771,478-85,798,657 Vitamin K-dependent gamma-
carboxylase 
HABP2 chr10:115,305,590-115,349,860 Factor VII activating protease (FSAP) 
HRG chr3:186,378,798-186,396,523 Histidine-rich glycoprotein 
KLKB1 chr4:187,143,672-187,180,125 Plasma kallikrein 
KNG1 chr3:186,415,098-186,461,178 Kininogen-1 
LMAN1 chr18:56,994,556-57,031,508 Lectin, mannose-binding, 1 
MCFD2 chr2:47,128,509-47,154,215 Multiple coagulation factor deficiency 
protein 2 
PLG chr6:161,118,225-161,175,585 Plasminogen 
PROC chr2:128,142,996-128,187,322 Vitamin K-dependent protein C 
PROS1 chr3:93,591,381-93,697,934 Vitamin K-dependent protein S 
PROZ chr13:113,805,468-113,827,194 Vitamin K-dependent protein Z 
SERPINA1 chr14:94,842,584-94,862,029 Alpha1-antitrypsin 
SERPINA10 chr14:94,749,150-94,764,608 Protein Z-related protease inhibitor 
SERPINA5 chr14:95,041,731-95,059,957 Plasma serine protease inhibitor 
SERPINC1 chr1:173,872,442-173,891,516 Antithrombin III 
SERPIND1 chr22:21,123,383-21,142,508 Heparin cofactor 2 
SERPINE1 chr7:100,764,879-100,783,047 Plasminogen activator inhibitor-1 
SERPINF2 chr17:1,636,130-1,659,059 Alpha2-antiplasmin 
SERPING1 chr11:57,360,027-57,382,826 Plasma protease C1 inhibitor 
TFPI chr2:188,328,458-188,424,219 Tissue factor pathway inhibitor 
VKORC1 chr16:31,101,675-31,111,276 Vitamin K epoxide reductase complex 
subunit 1 
Liver-specific markers included in the RNA design 
ALB 
 
Serum Albumin 
CD163 
 
CD163 molecule 
FBLN2 
 
Fibulin-2 
CD3G 
 
CD3 gamma molecule 
Negative control included in the RNA design 
HYAL4 
 
Hyaluronidase 4 
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Massive parallel sequencing 
The workflow for preparing custom sequencing libraries for massive parallel 
sequencing is illustrated in Figure 4.  
Figure 4. Library preparation for targeted next generation sequencing. 1) Genomic DNA is 
sheared into smaller fragments. 2) Biotinylated probes are designed to target a specific region 
of interest. 3) Probes are hybridized with the genomic sample and will only anneal to the 
targeted regions. 4) Streptavidin-coated magnetic beads are added to the sample. 5) The 
Streptavidin-coated beads bind to the biotinylated probes and the target DNA is extracted 
through magnetic separation. 6) Targeted DNA is eluted and the sequence library is ready.   
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DNA sequencing of hemostatic genes (Papers II-III) 
gDNA from whole blood was isolated using the QIAamp DNA Blood Midi Kit 
(Qiagen). Strand-specific sequencing libraries for gDNA-seq were prepared 
using a custom designed SureSelect kit (Agilent) according to the 
manufacturer’s protocols. Input amount of gDNA was 3 μg. Six or seven 
samples were pooled into one single 8 pM sequence library and multiplexed 
on one flowcell on the MiSeq platform (Illumina, San Diego, CA, USA) with 
150 bp paired-end reads.  
All raw sequence reads were quality controlled using FastQC (Babraham 
Bioinformatics, Cambridge, UK). Reads were trimmed (removal of adaptors 
and indexes) with Prinseq-lite (v0.20.3) and aligned to the human reference 
genome hg19 with Bowtie2 (v2.2.6). Genetic variants were called using 
HaplotypeCaller v3.4.36 (GATK, Broad Inst, Boston, Massachusetts, USA) 
with the GATK Best Practice recommendations, using a minimum required 
quality score of ≥40.  
RNA sequencing 
Because of the sensitive nature, RNA needs to be converted to cDNA before 
sequencing. This is performed with a reverse transcriptase in a mix with the 
four nucleotides in a PCR. During the reaction, a complementary strand of 
DNA is synthesized using the mRNA as a template. 
RNA sequencing of hemostatic genes (Papers II-III) 
Total RNA from liver tissue samples were extracted in biological duplicates 
(i.e., two separate pieces of liver tissue per individual) using the AllPrep 
DNA/RNA/miRNA Universal Kit (Qiagen). Strand-specific RNA-seq 
libraries were prepared for each duplicate separately using the custom-
designed SureSelect kit (Agilent) according to the manufacturer’s protocol. A 
total of 10-12 sample libraries were multiplexed per sequence lane using 125 
bp paired-end reads on the HiSeq 2500 sequencer (Illumina). Samples from 
two subjects were also sequenced using Illumina’s TruSeq kit for whole 
transcriptome analysis to identify possible weaknesses or biases in our custom-
designed kit (prepared as above). 
Sequence reads were trimmed with TrimGalore! (v.0.4.1) and aligned via 
STAR (v2.4.2) to N-masked individual-specific versions of the reference 
genome hg19, constructed using genotype data from the same samples. This 
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was performed to minimize downstream mapping biases for the ASE analyses, 
as recommended by GATK ASE best practices. Reads were counted for 
mRNA quantification using HTSeq (v.0.6.1) using default parameters and the 
results were compared between duplicates and between the custom and 
commercial library kits. 
Methylation sequencing 
Sodium bisulfite treatment of DNA converts all unmethylated cytosines in the 
sequence to uracils. This is achieved when bisulfite induces deamination of 
unmethylated cytosines in single stranded DNA, while methylated cytosines 
are protected against deamination. By sequencing the bisulfite treated gene and 
comparing it to an untreated reference sequence, it is possible to determine the 
DNA methylation status of the methylation sites in question. An illustration of 
bisulfite conversion is shown in Figure 5. 
 
Figure 5. Bisulfite conversion. Treatment with sodium bisulfite converts all unmethylated 
cytosines (C) to uracils (U), whereas the methylated cytosines remain unchanged. During the 
PCR, thymine (T) will be incorporated instead of the uracils, and the methylation status of 
each CpG can be determined. 
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Methylation sequencing of hemostatic genes (Papers III-IV) 
gDNA from blood was isolated as described above, and gDNA from liver 
tissue was isolated using the AllPrep DNA/RNAmini kit (Qiagen). The DNA 
was sheared to an average size of 250 bp and bisulfite converted with the EZ 
DNA methylation kit (Zymo Research, Irvine, CA, USA). The bisulfite-treated 
DNA was then used to prepare strand-specific sequencing libraries using the 
custom designed SureSelect kits (Agilent) according to the manufacturer’s 
protocols. All sample libraries were multiplexed in one sequence lane on the 
HiSeq 2500 (Illumina) with High Output mode and 100 bp paired-end reads, 
following the manufacturer's protocols. For comparison, gDNA isolated from 
two liver samples was also prepared using the SureSelectXT Methyl-seq target 
enrichment system for Illumina (Agilent), which is a commercially available 
methylation sequencing kit targeting 84 Mb of the genome, and sequenced in 
one lane on the HiSeq 2500 with the same options as described above. 
All raw output sequence reads were quality controlled using FastQC 
(Babraham). After removal of low-quality bases (Phred score <30), reads were 
trimmed with TrimGalore! (v.0.4.1) and aligned to an in-silico bisulfite 
converted version of the human reference genome hg19 with Bowtie2 (v. 
2.2.6.) Deduplication and methylation calling were performed with the 
Bismark pipeline (v.0.14.5) using default parameters. The SeqMonk software 
(v1.44.0; Babraham) was applied to visualize CpG methylation levels. 
Sequence data quantitation and downstream analyses 
Sequencing libraries for gDNA were prepared and sequenced at the Genomics 
Core Facility at the University of Gothenburg. For mRNA, a pilot of six 
samples were initially prepared and sequenced at the Genomics Core Facility. 
After evaluating the data, we prepared libraries for all samples (in biological 
duplicates), which were then sequenced at the National Genomics 
Infrastructure (NGI) at Science for Life Laboratory. Methylation sequencing 
libraries were both prepared and sequenced at NGI. 
Allele-specific expression analysis 
As conventional eQTL studies require large sample sizes, only few studies 
have been performed on human liver tissue. Furthermore, results from eQTL 
analyses are influenced by unmeasured confounding variables, and thus the 
reproducibility of eQTL studies is relatively low.165,166 The ASE approach is 
an alternative methodology to map putative SNPs affecting mRNA expression. 
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This method standardizes environmental and other confounding variables and 
is a powerful method for small sample sizes which facilitates analysis of more 
“hard to access” human tissues.72 For the purpose of studying genotype-
expression association in human liver tissue in Paper II, we thus chose the ASE 
approach. 
Analysis of allele-specific expression of hemostatic genes 
(Paper II) 
Read counts from the biological duplicates were merged prior to ASE analysis. 
ASE was then determined based on the allelic ratio of heterozygous SNPs in 
processed RNA sequencing data. The GATK HaplotypeCaller (v.3.4.36) was 
used to determine RNA zygosity using a minimum required quality score of 
≥60. The proportion of reference alleles versus total counts was calculated 
using ASEReadCounter v.3.4.46 (GATK), following GATK best practices 
where applicable. For the ASEReadCounter, a read depth of ≥ 10 and a quality 
score of ≥10 was required.  
Allele-specific DNA methylation analysis 
Since DNA methylation may be influenced by environmental factors (e.g. 
smoking, diet, and drugs)167, large sample sizes are required in order to study 
variation in methylation in relation to genetic variants between individuals. As 
a result, most mQTL studies to date have been performed in easy to access 
tissues such as blood, which is not necessarily the tissue of relevance. For the 
same reason, most mQTL studies have used high-throughput assays based on 
microarrays that cover less than 4% of all human CpG and mainly assay CpGs 
in promoters and CGIs.168 The alternative ASM approach requires genotyping 
of SNPs for differentiating the alleles and simultaneous measurements of DNA 
methylation at individual CpG sites. Both of these can be achieved by using 
targeted next-generation sequencing, which allows for the unbiased detection 
of all CpGs, including those within the gene body. For these reasons, we chose 
the ASM approach for the genotype-methylation studies in Paper III. 
Analysis of allele-specific DNA methylation in hemostatic genes 
Bisulfite-seq reads were aligned to an in-silico bisulfite converted version of 
hg19 reference genome, in which known SNP positions had been masked by 
the ambiguity base “N” prior to alignment to avoid potential read mapping 
biases toward higher mapping rates of the reference allele compared with the 
Martina Olsson Lindvall 
35 
alternative allele169, using Bowtie2 (v.2.2.6). SNPsplit (Babraham) was then 
used to determine the allelic origin of reads covering known SNP positions 
using individual-specific genotype data. Aligned reads were separated into two 
separate alignments (i.e. one major allele alignment and one minor allele 
alignment) based on the alleles of the overlapping SNPs. The methylation 
status was then called from the two alignments separately using Bismark 
(v.0.14.5), and the methylation level of each CpG was compared between the 
two alignments. In order to appropriately estimate methylation differences, we 
required a minimum of 30 reads per allele.  
 
Databases and tools 
The sequencing projects described earlier, and many others, make their data 
available for the research community in various ways. A considerable number 
of databases and browsers have been constructed to compile data from 
different studies and projects. For the purpose of this thesis, I will mention a 
subset of these: 
The Single Nucleotide Polymorphism Database (dbSNP)170: Contains 
information on genetic variation for several species, including humans, and is 
developed and hosted by the National Center for Biotechnology Information 
(NCBI) in collaboration with the National Human Genome Research Institute 
(NHGRI). This database was used for SNP annotation in Papers II and III. 
The Genotype-Tissue Expression (GTEx) project66: A database of correlations 
between genotype and tissue-specific gene expression that is based on RNA 
sequencing data from several human tissues from genotyped donors. GTEx 
was used to assess liver expression of the targeted hemostatic genes 
investigated in Papers II-IV 
Ensembl171: A genome browser with reference datasets, with much focus on 
annotation. Ensembl is part of the European Bioinformatics Institute (EMBL-
EBI) at the European Molecular Biology Laboratory (EMBL). Ensembl was 
used for exon annotation in Paper II, and for genomic context annotations in 
Papers II-IV. 
The NHGRI GWAS catalog172: A searchable catalog of published genome-
wide association studies, founded by NHGRI and hosted by the EMBL-EBI. 
This library was used to assess if any of the expression and methylation 
associated SNPs identified in Paper II and III were associated with circulating 
levels of the respective proteins or other relevant traits. 
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Phenoscanner173: A database of results from published human GWAS, eQTL, 
pQTL, mQTL, and metabolite QTL data. This database was used to assess if 
the identified ASE and ASM-SNPs in Papers II and III had previously been 
associated with circulating hemostatic factors or other relevant traits. 
University of California, Santa Cruz (UCSC) genome browser174: An 
interactive website with genome sequence data integrated with a large 
collection of annotations from various projects. The UCSC genome browser 
was used to assay potential regulatory regions around hemostatic genes in 
order to determine the upstream and downstream distance to be included in the 
targeted sequencing design used in Papers II-IV. 
HaploReg175: A tool based on data from ENCODE for the chromatin state and 
protein binding annotation of SNPs. We used this tool for assessments of 
promoters and enhancers overlapping the ASE- and ASM-SNPs identified in 
Papers II and III. 
Statistical analyses 
In Paper I, differences in mRNA levels, protein concentrations, and degree of 
histone acetylation between HDAC inhibitor-treated cells and control-treated 
cells were determined by the unpaired Student’s t-test. A P-value <0.05 was 
considered statistically significant. Statistical analyses were performed using 
IBM SPSS for Windows (v.20, release 20.0.0). 
In Paper II, allele-specific expression was estimated by binomial testing in 
ASEReadCounter (v3.4.46; GATK). Further, for variants to be classified as 
ASE sites, the allelic imbalance ratio had to be <0.35 or >0.65 in at least one 
individual, with an average of ≤0.4 or ≥0.6 between all heterozygous 
individuals. 
In Paper III, differences in methylation levels between alleles for each 
individual were weighted by their inverse variances and summed. The sum was 
then scaled by its standard error to form a Z-statistic. A P-value less than 0.05 
was considered statistically significant. Further, a percent methylation 
difference >20% between the two alleles was required in order for CpGs to be 
classified as displaying ASM. Statistical analyses were performed using R (v. 
3.6.1). 
In Paper IV, we used Pearson’s correlation to evaluate correlations in 
methylation levels between paired liver and blood samples. A minimum of five 
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paired liver-blood samples per CpG was set as a requirement for this test and 
a Bonferroni adjusted P-value of <0.05 was considered statistically significant. 
In addition to Bonferroni correction for multiple testing, we also performed a 
less conservative control of Type I errors using false discovery rate (FDR), 
with a significance cutoff of 0.05. Correlations for average methylation across 
all subjects between liver and blood were calculated using Pearson’s 
correlation. All statistical analyses in Paper IV were performed using R (v. 
3.6.1). 
Ethical approvals and considerations 
For Paper I, all donated brain tissues were collected with the full consent of the 
next of kin and in line with ethics approval from the University of Auckland 
Human Participants Ethics Committee (ref 011654). For Papers II-IV, written 
informed consent was obtained from all participants, and the study was 
approved by the Ethics Committee at the University of Gothenburg (dnr 665-
13). 
There were no medical risks for patients participating in the studies. Thus, the 
only relevant risks concern patient integrity with regard to personal and genetic 
information. To overcome this, all samples were coded immediately after 
collection and cannot be directly traced to the participant’s name or social 
security number. The genetic analyses did not provide participants with any 
information of relevance for their prognosis or for risk factors regarding other 
diseases. There are no foreseeable benefits for the patients that chose to 
participate. However, knowledge obtained in these studies may be of value for 
other patient categories further on. 
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RESULTS AND DISCUSSION 
Regulation of t-PA in the human brain and brain-
derived cells (Paper I) 
Following treatment with the HDAC inhibitors TSA and MS-275 for 24 hours, 
we observed a 2 to 3-fold increase in t-PA mRNA in astrocyte and neuron 
cultures compared to the control-treated cells. At the protein level, we also 
found that t-PA antigen concentrations in the astrocyte-conditioned media 
increased 1.5 to 2-fold in response to HDAC inhibitor treatment (Figure 6). 
As HDACs also act on non-histone proteins that may influence gene 
regulation, such as transcription factors, we next performed a ChIP assay on 
astrocytes with antibodies directed against acetylated histones H3 and H4 (both 
markers of gene activation). Treatment with MS-275 and TSA resulted in a 
significant increase in H3 acetylation in the t-PA promoter as compared to 
control treated cells (Figure 7). This finding confirms that HDAC inhibitors 
act directly on histone H3 acetylation in the t-PA promoter, and this 
mechanism could thus explain the observed increase in t-PA gene expression 
after the inhibition of histone deacetylation. No significant increase in histone 
H4 acetylation was observed following HDAC inhibitor treatments. 
In cortical and hippocampal brain tissues, as well as in cultured astrocytes and 
neurons, we observed a high degree of DNA methylation (50–100%) in the t-
PA promoter from position −618 to −366 relative to the transcription start site 
(TSS), whereas the CpGs located between position −121 to +94 showed no or 
minimal methylation (0–20%). The observed hypomethylation at the latter 
positions is in line with previous results from human endothelial cells, whereas 
human hepatocytes exhibit a considerably higher degree of DNA methylation 
in the same genetic region.176 Neurons, astrocytes, and endothelial cells have 
all been shown to have a high basal t-PA gene expression145,177, whereas 
hepatoma cells and hepatocytes have a low t-PA gene expression176. Thus, the 
expression level of t-PA appears inversely correlated with the degree of 
promoter methylation, which is expected for genes that are under epigenetic 
influence. Taken together, our results suggest that epigenetic mechanisms are 
involved in the regulation of t-PA in the human brain. However, the 
significance of these mechanisms needs to be examined further. 
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Figure 6. Treatment with histone deacetylase (HDAC) inhibitors resulted in a significant 
increase in t-PA expression in cultured human astrocytes and neurons. (A) t-PA mRNA and 
protein expression levels in cultured human astrocytes following treatment with 1 μM 
trichostatin A (TSA) or 10 μM MS−275. (B) t-PA mRNA expression levels in cultured human 
neurons following treatment with TSA or MS-275. Cells were treated for 14 or 24 hours. Results 
are shown as fold induction compared with control-treated cells and presented as mean ± SEM. 
Each data point represents the average of three independent treatment series performed on two 
different occasions. Response to treatment was evaluated by the unpaired Student’s t-test: 
*P≤0.05, **P≤0.01, and ***P≤0.001. 
 
 
 
Figure 7. Treatment with histone deacetylase (HDAC) inhibitors resulted in a significant 
increase in acetylation of histone H3 but not histone H4 in the t-PA promoter. Results are 
presented as mean percentage of input DNA ± SEM. Each data point represents the average of 
two independent ChIP experiments performed in triplicate. Differences in histone acetylation 
levels were determined by the unpaired Student’s t-test. *P≤0.05, **P≤0.01, and ***P≤0.001.  
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Sequencing output and evaluation of the targeted 
design (Papers II-IV) 
We made a custom design for the targeted analyses of 78 genes expressed in 
human liver, and 35 of these were selected for the analyses of hemostatic genes 
predominantly expressed in liver in Papers II-IV. This design for DNA 
sequencing yielded approximately 300 million (M) reads per sample, with a 
sequencing depth of ~100x. 
For mRNA sequencing, approximately 25 M reads were generated for each 
sample. All transcripts of interest were identified. The negative control was not 
detected. All RNA samples were sequenced in biological duplicates. Read 
counts and normalized expression values were highly replicable between these 
duplicates (Figure 8A). Two samples were also sequenced using Illumina’s 
TruSeq kit to identify possible weaknesses or biases in our custom designed 
kit. Assessment of the data showed no significant bias in expression values 
between the two kits (Figure 8B). Furthermore, the custom design gave more 
sequencing coverage on our transcripts of interest, and thus this approach was 
more data efficient and cost-effective.  
For methylation sequencing, approximately 10-20 M reads per sample were 
generated, and the sequencing depth was 50x. We evaluated the sequencing 
output when using the commercial 84 Mb kit compared to the custom kit. The 
84 Mb kit is biased towards CpG islands, promoters and regulatory regions. 
However, according to the manufacturer’s specifications, all of our regions of 
interest (i.e. the 35 hemostatic genes) are included in this design. We compared 
the depth and coverage within our targeted regions between the two kits. The 
comparison showed that our custom kit was superior to the commercial kit in 
both aspects (Figure 9).  
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Figure 8. RNA expression data. (A) Comparison of normalized expression values (TPM) for 
each of the 35 genes between duplicates for all 17 samples. (B) Comparison of expression values 
of the 35 genes for one sample prepared and sequenced using our custom capture kit and the 
TruSeq whole transcriptome kit (Illumina). 
 
 
 
 
 
 
 
 
Figure 9. Comparison of sequencing depth and coverage for data generated with the custom-
designed capture kit for methylation sequencing and the commercial SureSelect enrichment kit 
(Agilent). (A) Sequencing depth over CpGs within the targeted 35 regions. (B) Sequencing 
coverage for one sample prepared and sequenced using our custom capture kit (outer data track) 
and the commercial kit targeting 84 Mb genome-wide (inner data track). Sequencing depth 
throughout the 35 targeted regions is represented by the data track colour intensity, where darker 
red indicates greater sequence coverage.  
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Hemostatic genes exhibit allele-specific expression in 
human liver tissue (Paper II) 
Using the targeted DNA- and RNA-sequencing described above, our study 
identified ASE in 21 of the 35 analyzed hemostatic genes, across a total of 53 
SNPs, in liver. Using publicly available database sources173, we found that 
seven of these ASE-SNPs had previously been associated with expression of 
the respective mRNA in liver tissue in eQTLs studies, and 32 had been 
identified as eQTLs in other cell types or tissues. As the sample size greatly 
affects identification of eQTLs, more readily available tissues, such as blood, 
tend to be overrepresented in eQTL datasets. This is likely the reason for the 
fact that a much higher number of ASE-SNPs had previously been identified 
as eQTLs in other tissues, as compared to liver.  
More importantly, we also identified novel genotype–expression associations. 
Fourteen (26%) of the ASE-SNPs identified in this study had no previous 
evidence of association to mRNA expression, either in the liver or in other 
tissues. We assessed the novel ASE-SNPs for overlap with regulatory motifs 
and chromatin states in their genomic location in liver tissue. According to 
HaploReg175, 13 had chromatin states indicative of promoters or enhancer 
elements in the liver, and 11 of these were predicted to abolish, create, or 
change the affinity of one or several transcription factor binding sites. Five of 
the novel ASE-SNPs had previously been associated with circulating levels or 
activity of their respective proteins in publicly available GWAS data173, and 
two additional ASE-SNPs could be associated with concentrations of their 
respective protein in another published study109 or in data from our own case–
control study on ischemic stroke, SAHLSIS178. Furthermore, seven novel ASE-
SNPs, including two of the ones associated with circulating proteins, had 
previously been associated with other traits or diseases related to thrombosis 
and hemostasis, including activated partial thromboplastin time, bleeding, 
CAD, MI, and VTE in public GWAS data.173 Taken together, our assessment 
of previously published data provided evidence for involvement in thrombotic 
or hemostatic processes for 11 of the 14 novel ASE-SNPs. The remaining three 
SNPs have no previous mention in the literature, as far as we can tell. These 
were located in the genes encoding coagulation FX (F10; rs3212994), 
kininogen 1 (KNG1, rs5030100), and alfa 1-antitrypsin (SERPINA10; 
rs201774333). However, the F10 SNP had a chromatin state indicative of a 
promoter in liver tissue and was predicted to alter two regulatory motifs 
according to HaploReg. The ASE-SNP in KNG1 had an enhancer chromatin 
signature in liver, and was predicted to alter the binding site of three 
transcription factors. The SERPINA10 SNP had an enhancer chromatin 
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signature. Thus, all novel ASE-SNPs that we identified have features 
indicative of a plausible biologically relevant function and may be candidates 
for future functional studies. We envisage that this data set could be used by 
the hemostatic research community. For example, if a novel association 
between a SNP in one of the 35 hemostatic genes investigated here and a 
thrombotic or bleeding trait is discovered, the present data can be used to 
evaluate if this SNP displays ASE in the liver. In this way, it could be a 
stepping stone for designing appropriate experimental studies. Our results 
further provide support for the strengths of the allele-specific approach in 
studies where collection of the relevant tissue, and thereby sample size, is a 
limiting factor. 
Allele-specific DNA methylation of hemostatic genes in 
human liver (Paper III) 
As a next step, we investigated the presence of ASM in liver for the same 35 
hemostatic genes. We identified 116 CpG sites displaying significant allelic 
methylation imbalance of 20% or more in at least one sample. These CpGs 
were found in 24 genes, and were associated with 112 SNPs. The majority 
were located in gene bodies, and an enrichment of ASM was observed in the 
genomic context “first exons”. This is in line with previous studies showing 
that CpG sites that are associated with expression levels are enriched in 
enhancers, gene bodies, CpG island shores, and in the first exon, but not in 
promoter regions.16,179 Nearly all (94%) of the ASM-associated SNPs (ASM-
SNPs) in our study had chromatin states indicative of promoter or enhancer 
elements in liver, which is also in line with previous studies in other tissues 
that have shown that cis-acting methylation-associated SNPs are enriched in 
regulatory chromatin domains and transcription factor binding sites.180-182  
We investigated whether the identified ASM-SNPs and high LD proxies 
(r2≥0.8 in 1000G European panel) were associated with mRNA expression 
using mRNA-seq data derived from the same individuals. However, as we 
were underpowered for inter-individual analysis, we also queried these ASM-
SNPs in a publicly available database173 of liver tissue eQTLs. We found 
evidence of association with mRNA expression in liver tissue for 22% of the 
identified ASM-SNPs using these approaches. Furthermore, 46% ASM-SNPs 
had been identified as eQTLs for their respective genes in tissues other than 
liver. Thus, for 68% of the identified ASM-CpG, our findings suggest that 
DNA methylation regulated by genetic variants in cis may be a mechanistic 
link between previously identified genotype-expression associations. 
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We further investigated if the ASM-SNPs had been associated with circulating 
plasma proteins. Twenty-nine percent had been associated with the respective 
protein concentrations or activity in publicly available pQTL and GWAS 
datasets173, and these included five ASM-SNPs with no previously reported 
eQTLs that were associated with plasma fibrinogen, KNG1, SERPINF2, and 
FSAP concentrations. We also assessed associations of ASM-SNPs with 
relevant disease and non-disease phenotypes in published data. Two ASM-
SNPs in F5 (rs3766110 and rs3766111) had been associated with VTE 
(http://www.ukbiobank.ac.uk), one ASM-SNP in TFPI (rs8176546) had been 
associated with CAD183, and one in F2 (rs2070851) had been associated with 
ischemic stroke184. Furthermore, 34 additional ASM-SNPs had been associated 
with other phenotypes related to hemostasis such as plasma concentrations of 
glycoproteins and various coagulation factors, and vascular or heart problems.  
The CpG displaying the highest degree of ASM in our study was located in 
VKORC1, with a methylation difference of 47% in favor of the minor allele. 
The SNP (rs8050894) connected to this CpG was associated with VKORC1 
mRNA levels both in our RNA-seq data and in public liver eQTL data, and it 
was also the top hit in a GWAS on warfarin maintenance dose185. Several 
clinical trials are investigating the value of genotype-guided dosing of oral 
anticoagulants such as warfarin and novel oral anticoagulants (NOACs)186-189, 
and another SNP in almost perfect LD with the VKORC1 ASM-SNP has 
already been used in trials of pharmacogenetics-based versus conventional 
dosing of warfarin with promising results189,190. In addition to VKORC1, we 
also identified ASM in F2 and F10, which both are targets for NOACs, and in 
11 other hemostatic genes that are current targets of anti-thrombotic, anti-
fibrinolytic, or other related drugs. In line with our results, recent studies have 
reported that DNA methylation may contribute to the variability in response to 
warfarin188. Similar findings have been made for aspirin and clopidogrel191. 
Thus, methylation influenced by genetic variation in cis may not only provide 
a mechanistic link between the non-coding genetic variants and the phenotypic 
variation observed in circulating hemostatic proteins and prothrombotic 
diseases, but also in the phenotypic variation in response to drugs.  
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Overlap between allele-specific expression and DNA 
methylation (Papers II-III) 
Variants regulating mRNA expression in cis tend to be found in promoter 
regions, whereas variants that regulate DNA methylation tend to occur in other 
regulatory regions such as enhancers and insulators192, and previous studies 
have found only a small overlap between variants tagging cis-acting expression 
and DNA methylation.20,182,193-196 We thus compared all ASE-SNPs and ASM-
SNPs identified in Papers II and III, and found that only 10 SNPs (<1%) were 
associated with both ASE and ASM. Thus, this outcome is in line with the 
results of previous studies, and highlights the complimentary nature of 
conducting both types of mapping. 
Correlation of DNA methylation levels between liver 
and blood (Paper IV) 
Given the difficulty in obtaining liver tissue samples, it is of great importance 
to know whether blood can be used as a proxy for liver for studies of DNA 
methylation. In Paper IV, we thus used paired liver and blood samples and 
found that the correlation in methylation between liver and blood was in 
general very low. When applying a Bonferroni adjusted P-value cut-off of less 
than 0.05, we found significant within-subject correlations in methylation 
between liver and blood for 354 CpG sites, i.e. 3.4% of all investigated 
methylation sites. The majority of the correlated CpG sites showed a strong 
positive correlation (r>0.74 throughout) between methylation levels in blood 
and liver. Significantly correlated CpGs were over-represented in introns, 
whereas they were depleted in CGI shores, promoters, exons, exon-intron 
boundaries, and in the first intron.  
For comparison, we also examined the level of CpG methylation correlation 
between liver and blood across samples. Here, we calculated mean methylation 
values for each CpG across each tissue, and then calculated the overall 
correlation of all CpGs between liver and blood. This across-subject 
correlation was substantially higher (mean r=0.68) compared to the mean 
within-subject correlation described above.  
Two main correlation patterns were identified among the significant CpGs: 1) 
“continuous” correlation (~24% of the CpGs), where the methylation levels 
spanned a wide range in a linear fashion, and 2) a trimodal correlation pattern 
(~47% of CpGs) with methylation levels around 0%, 50% or 100%. The latter 
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correlation pattern is most likely due to genotype-dependent DNA methylation 
such as mQTL or ASM. Thus, from a biomarker perspective, the CpGs 
displaying the trimodal pattern could potentially be assayed using regular DNA 
sequencing or genotyping, which require less extensive laboratory work and 
data management in comparison to methylation sequencing.  
CpGs displaying variable DNA methylation in liver are more likely to be of 
biological relevance for the investigated liver-expressed hemostatic genes. Of 
the 354 CpGs showing a significant correlation between liver and blood, 
around 90% displayed variable methylation in liver, defined as a methylation 
range differing at least 5% after exclusion of methylation values above the 90th 
percentile and below the 10th percentile for each CpG, in liver. Both the 
trimodal and the continuous group were represented among these. However, 
we believe that the subset of CpGs that both display variable methylation in 
liver and a continuous correlation pattern for methylation in liver and blood 
will be the most useful in the sense of being methylation blood biomarkers for 
liver. Of all analyzed CpGs, 23% exhibited both these properties. The highest 
number of CpGs with these properties was found in F7 (25 CpGs), and all were 
located in the F7 promoter and/or in a CGI partly overlapping the promoter. 
Plasma concentrations of FVII have previously been shown to associate with 
incident MI and ischemic stroke.197-200 Additionally, methylation of the F7 
promoter in blood (peripheral blood mononuclear cells) has been linked both 
to plasma concentrations of FVIIa and to CAD.201 In light of this, our findings 
do not only demonstrate that F7 promoter methylation levels in blood can be 
used as a surrogate measure for methylation in liver tissue, but also suggest 
that F7 promoter methylation in the liver may contribute to the regulation of 
plasma concentrations of FVII. 
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CONCLUSIONS TO GIVEN AIMS 
Histone acetylation affects the regulation of t-PA mRNA expression in human 
astrocytes and neurons. Further, expression levels of t-PA are inversely 
correlated with the degree of DNA methylation in the t-PA promoter. Taken 
together, our findings suggest involvement of epigenetic mechanisms in t-PA 
gene regulation in the human brain. 
Our study provides the first detailed map of DNA methylation patterns in 
hemostatic genes in liver. The results show that the promoters of these genes 
are generally hypomethylated in the liver, as expected for actively transcribed 
genes. The methylation levels in gene bodies were in general higher, although 
much more variable.  
The investigated hemostatic genes display a high degree of allele-specific 
expression and DNA methylation in liver. Our findings further demonstrate 
that analyses of allelic imbalance in expression and methylation are powerful 
methods to identify putative cis-acting variants involved in gene regulation. 
In general, DNA methylation levels in the hemostatic genes correlate poorly 
between liver tissue and peripheral blood within individuals. However, our 
findings suggest that blood methylation patterns may potentially be used as 
proxies for liver methylation for a limited subset of CpGs. 
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CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
During the past decade, genome-wide association studies (GWAS) have 
successfully identified many genetic variants associated with complex diseases 
and traits. However, these variants typically explain only a small fraction of 
the estimated heritability. Other mechanisms, such as epigenetics, have been 
proposed to account for this “missing heritability”. As complex diseases are 
affected by many different variants with small effects, combining the effects 
of multiple SNPs with epigenetic information may explain more of the 
heritability and improve predictive utility of genetic information. 
The results presented in this thesis suggest involvement of genetic and 
epigenetic interactions in the regulation of a set of hemostatic genes 
predominantly expressed in the liver, and provide evidence for regulatory 
involvement for a number of novel genetic variants. It may be hypothesized 
that the combined effects of several SNPs associated with a prothrombotic state 
might confer risk of thrombotic disorders such as ischemic stroke or venous 
thromboembolism, whereas SNPs associated with lower plasma 
concentrations of coagulation factors levels might confer risk for bleeding and 
hemorrhagic stroke. It would be of great interest to test this hypothesis by 
constructing a genetic risk score (GRS) based on SNPs identified in this thesis, 
supplemented with additional SNPs that have been identified through GWAS 
to associate with circulating levels of prothrombotic factors and/or other 
relevant phenotypes. The GRS could then be tested for association with related 
traits, such as ischemic stroke, ischemic stroke subtypes, stroke outcomes, or 
to VTE, in other available studies. Such analyses could potentially provide 
further insights into the relative impact of the hemostatic pathway for ischemic 
stroke and VTE. 
Knowledge of tissue-specific DNA methylation provides a foundation for 
studies of methylation-mediated regulation and tissue diversity in expression. 
Methylation of CpG dinucleotides are undoubtedly the most abundant and 
well-studied form of DNA methylation and has been convincingly implicated 
in chromatin organization and gene regulation. However, DNA methylation 
may also be found at cytosines in non-CpG contexts, such as CHG and CHH 
(where “H” corresponds to an A, T or C nucleotide). Non-CpG methylation 
has been associated with tissue-specific cell functions202 and with 
transcriptional repression in brain cells203, and promoter non-CpG methylation 
has been correlated with gene repression204. However, this phenomenon is not 
well studied, and the mechanisms and effects of non-CpG methylation are still 
poorly understood. The research performed within the scope of the present 
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thesis has focused on CpG methylation. However, the sequence data generated 
here may in the future also be used for high-resolution investigations of non-
CpG methylation in liver and blood in the future. 
Genetic and epigenetic mechanisms can affect proteins, phenotypic variation, 
and expression in various ways. Alternative splicing (AS) is a regulatory 
mechanism acting on the transcribed RNA which mainly involves “exon 
skipping”. Individual exons may be included in the final mRNAs under some 
conditions or in specific tissues, but omitted in others. This process gives rise 
to multiple mRNA isoforms generated from the same gene, and increases 
protein diversity significantly. AS is regulated in a cell type-specific manner 
and is influenced by genetic variation.205 More recently, DNA methylation has 
also been implicated in AS.206 Most genes are subject to some form of AS, and 
hemostatic factors are no exception.207,208 AS has also been implicated in 
various diseases209, including stroke210 and cardiometabolic disease211. High-
throughput RNA sequencing methods have greatly facilitated analysis and 
identification of AS, and the deep RNA sequencing data used for the purpose 
of this theses are well suited for such investigations. In our dataset, information 
on genotypes and DNA methylation is available from the same individuals, 
and the effects of these features on hemostatic AS could be comprehensively 
investigated. Such analyses have the potential to increase our knowledge and 
understanding of the regulation of hemostatic genes and proteins further.   
Three of the four papers included in this thesis are based on targeted gDNA, 
RNA, and methylation sequencing data. The main advantages of the custom 
targeted design are that a much higher coverage and sequencing depth for the 
specific regions of interest can be achieved. For RNA sequencing in particular, 
whole transcriptome sequencing methods tend to generate much lower 
coverage for less abundant transcripts. Due to the wide range in expression 
levels between different mRNA molecules, more abundant transcripts will be 
sequenced to a higher extent and more reads will be generated for these. Thus, 
both transcript detection and quantification precision will increase with a 
deeper sequence level. The extensive sequence depth resulting from targeted 
RNA sequencing is also useful for identification of novel exons and transcript 
isoforms that may not be readily detectible in whole RNA-seq data. 
Furthermore, both expression and DNA methylation vary between different 
tissues within one individual, as well as between different individuals. 
Therefore, these types of high-throughput sequencing data are warranted for 
additional samples, gene sets, and tissue types to fully be able to understand 
the dynamic nature of biological diversity and to unravel the genetic as well as 
non-genetic mechanisms involved in gene regulation 
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